Latest News

Stay up to date with the latest stock market news from around the world. From breaking news written by our finance analysts to event-driven market news on a global scale.

NasdaqGS:NBIS
NasdaqGS:NBISSoftware

A Look At Nebius Group (NBIS) Valuation After Major AI Data Center Plan And Mega Tech Partnerships

Nebius Group (NasdaqGS:NBIS) is in focus after announcing a US$10b AI data center project in Lappeenranta, Finland, alongside large supply deals with Meta and Microsoft and a US$2b investment from Nvidia. See our latest analysis for Nebius Group. After a sharp rally recently, Nebius now trades at US$101.95, with a 30 day share price return of 12.02% and a year to date share price return of 13.34%. Its 1 year total shareholder return of 316.97% suggests very strong longer term momentum, while...
NasdaqGS:INCY
NasdaqGS:INCYBiotechs

Incyte HS Data Tests New Leadership And Povorcitinib Growth Potential

Incyte (NasdaqGS:INCY) released 54-week pivotal Phase 3 data from its STOP-HS program for povorcitinib in moderate to severe hidradenitis suppurativa (HS). The data show durable efficacy across multiple clinical response thresholds and improvements in patient quality of life at 54 weeks. Safety results were consistent over the long term, supporting the overall benefit risk profile of povorcitinib in HS. This is the first publication of long-term pivotal data for povorcitinib in HS ahead of...
ENXTPA:SK
ENXTPA:SKConsumer Durables

Assessing SEB’s Valuation As A €1.16b Share Buyback Gets Underway

How SEB’s new share buyback shapes the investment story SEB (ENXTPA:SK) has launched an €1.16b share repurchase program, authorized to cover up to 10% of its share capital, giving investors a fresh catalyst to reassess the stock’s risk and reward profile. See our latest analysis for SEB. SEB’s new buyback comes after a weaker share price patch, with a 30 day share price return of an 8.76% decline and a 1 year total shareholder return of a 45.48% loss. This suggests sentiment has been under...
TSX:CFP
TSX:CFPForestry

New Share Buyback Plan Might Change The Case For Investing In Canfor (TSX:CFP)

In March 2026, Canfor Corporation (TSX:CFP) announced that its Board of Directors had authorized a new normal course issuer bid to repurchase up to 5,821,442 common shares, or 5% of its 116,428,846 shares outstanding, for cancellation through March 22, 2027, following the expiry of its prior plan on March 20, 2026. This fresh buyback authorization signals that Canfor sees value in reducing its share count, which can reshape how investors assess ownership and capital allocation...
LSE:DGE
LSE:DGEBeverage

Assessing Diageo’s (LSE:DGE) Valuation As Income Investors Revisit The Stock

Why Diageo (LSE:DGE) Is Back on Income Investors’ Radar Diageo (LSE:DGE) is drawing fresh attention after a period of weaker share performance, with the stock showing negative returns over the past year and past 3 months despite remaining a large, profitable spirits group. See our latest analysis for Diageo. Short term momentum looks weak, with a 30 day share price return of 13.32% and a year to date share price return of 13.23%. In comparison, the 1 year total shareholder return of 29.97%...
NYSE:ZIM
NYSE:ZIMShipping

How Expected Earnings and Revenue Pressure At ZIM Integrated Shipping Services (ZIM) Has Changed Its Investment Story

ZIM Integrated Shipping Services recently saw sentiment soften as investors reacted to projections for a substantial year-over-year decline in its upcoming quarterly earnings and revenue. The lack of recent changes in consensus earnings estimates, alongside a Hold rating on the Zacks scale, underscores lingering uncertainty over ZIM’s near-term operating outlook. Against this backdrop of expected earnings and revenue pressure, we will examine how this cautionary earnings setup could reshape...
ASX:ALL
ASX:ALLHospitality

Aristocrat Leisure Buy-Back Update Prompts Fresh Look At Valuation And Capital Management

Share buy-back update puts Aristocrat Leisure in focus Aristocrat Leisure (ASX:ALL) has updated the market on its on-market share buy-back, reporting cumulative repurchases of more than 22 million ordinary shares as of 31 March, under its ongoing capital management program. See our latest analysis for Aristocrat Leisure. The latest buy-back update lands as the 1-day share price return of 2.98% contrasts with a 90-day share price decline of 19.77% and a 1-year total shareholder return of...
NYSE:GOLD
NYSE:GOLDRetail Distributors

Renewed Safe‑Haven Interest in Gold Might Change The Case For Investing In Gold.com (GOLD)

Recent commentary on Gold.com highlights how gold’s traditional role as a haven asset held firm despite a sharp price drop during the Middle East conflict, when liquidity needs temporarily pushed prices lower. The analysis points out that investors are now rebuilding gold exposure as concerns over global debt, currency debasement, and geopolitical risks persist, supporting renewed attention on the metal. We’ll now explore how persistent geopolitical and macroeconomic risks highlighted by...
NasdaqGS:AMGN
NasdaqGS:AMGNBiotechs

Will FDA Tavneos Safety Scrutiny and New Lung Cancer Combo Trial Change Amgen's (AMGN) Narrative?

Zai Lab announced in the past that it will collaborate with Amgen on a global Phase 1b trial combining Zai Lab’s DLL3-targeting ADC zocilurtatug pelitecan with Amgen’s IMDELLTRA for patients with extensive-stage small cell lung cancer. Separately, the FDA’s identification of dozens of Tavneos-linked liver injury cases, including severe events and deaths, raises fresh questions about Amgen’s safety and regulatory risk profile. Next, we’ll explore how the FDA’s Tavneos safety concerns could...
NasdaqCM:ONCY
NasdaqCM:ONCYBiotechs

Oncolytics Biotech’s U.S. Move Resets Regulatory Path And Valuation Debate

Oncolytics Biotech (NasdaqCM:ONCY) has completed its domestication from Canada to the United States. The company has relocated its headquarters to San Diego, with the move now effective. Oncolytics Biotech is now classified as a U.S. domestic issuer under the U.S. regulatory framework. The domestication is intended to support operational efficiencies and access to U.S. capital markets. For you as an investor, this shift touches on both regulation and capital access. Oncolytics Biotech is an...
NYSE:DUK
NYSE:DUKElectric Utilities

Duke Energy Recycles Gas Sale Proceeds Into Grid And Generation Growth

Duke Energy (NYSE:DUK) has completed the sale of its Tennessee Piedmont Natural Gas business to Spire. The company plans to use the proceeds to support its regulated capital investment plan over the next five years. The move marks a shift in Duke Energy's portfolio toward grid and generation projects while aiming to manage customer costs. Duke Energy, trading at about $130.9 per share, is using this transaction to refine where its capital is focused. The company has delivered an 11.5%...
NYSE:KO
NYSE:KOBeverage

Coca-Cola’s US$1b Africa Push And What It Could Mean For Valuation

Coca-Cola plans a long term investment of $1 billion in South Africa to expand production and distribution capacity. The company is acquiring a majority stake in Coca-Cola Beverages Africa, covering South Africa and 14 additional African markets. The investment focuses on local hiring, operational expansion and deeper integration with regional partners over multiple years. Coca-Cola (NYSE: KO) is adding a major Africa focused chapter to its global story with this $1 billion commitment. The...
TSX:ABX
TSX:ABXMetals and Mining

A Look At Barrick Mining (TSX:ABX) Valuation After Strong Quarterly Results And Shareholder Return Updates

Barrick Mining (TSX:ABX) is back in focus after quarterly results showed higher gold production, lower costs, favorable commodity prices, and record cash flow, along with increased share repurchases, a higher dividend, and a new operational review. See our latest analysis for Barrick Mining. The share price reaction has been sharp, with a 3.24% 1 day and 8.85% 7 day share price return after results. This comes even though the 30 day share price return shows a 15.15% decline and the year to...
ASX:BHP
ASX:BHPMetals and Mining

Does BHP’s Copper and Potash Capex Pivot Reshape The Bull Case For BHP Group (ASX:BHP)?

BHP Group has recently advanced its copper and potash focus, including lodging the Escondida New Concentrator for environmental assessment, progressing the Resolution Copper project in the U.S., and increasing planned FY26 capex to US$11.00 billion across copper, iron ore and potash. At the same time, governments building strategic mineral reserves and BHP’s large Jansen potash development in Canada highlight how critical minerals policy and long-life projects are increasingly shaping the...
ENXTAM:AGN
ENXTAM:AGNInsurance

Is It Time To Reassess Aegon (ENXTAM:AGN) After A Strong Multi Year Share Price Run

Wondering if Aegon shares are giving you enough value for the risk you are taking, especially after a strong multi year run? The stock last closed at €6.39, with returns of 3.5% over 7 days, 0.9% over 30 days, negative 3.7% year to date, 11.0% over 1 year, 91.4% over 3 years, and 101.8% over 5 years. Recent headlines around Aegon have focused on its position within the insurance sector and how its capital strength, business mix, and exposure to different markets compare with peers. This...
SEHK:6181
SEHK:6181Luxury

Laopu Gold (SEHK:6181) Valuation Check As Strong Earnings Dividends And Guidance Draw Fresh Interest

Laopu Gold (SEHK:6181) has drawn fresh attention after reporting full year 2025 results, issuing first quarter 2026 guidance, proposing higher final dividends, and flagging amendments to its articles of association. See our latest analysis for Laopu Gold. Laopu Gold’s latest earnings, dividend proposal and first quarter guidance arrive after a mixed share price run, with a 5.3% 90 day share price return but a 16.6% 1 year total shareholder return decline from the latest HK$650.5 level. If...
NasdaqCM:SMPL
NasdaqCM:SMPLFood

Does Atkins’ Slowdown and Margin Pressure Reshape the Bull Case For Simply Good Foods (SMPL)?

In recent weeks, Simply Good Foods has faced mounting concerns as Atkins brand sales declined in consecutive quarters and rising costs pressured margins, prompting scrutiny of its growth outlook. Beyond the immediate slowdown, the key question now is whether stronger brands like Quest and OWYN can offset Atkins’ weakness and reshape the company’s long-term earnings mix. We’ll now examine how Atkins’ sales slump and margin pressure affect Simply Good Foods’ existing investment narrative built...
NYSE:BABA
NYSE:BABAMultiline Retail

Is Alibaba Group Holding (BABA) Pricing Reflect Its Recent Share Price Weakness?

If you are wondering whether Alibaba Group Holding's share price offers value right now, or if the market is pricing it fairly, this breakdown will help you connect the current price with what the business may be worth. The stock last closed at US$123.73, with returns of a 4.7% decline over 7 days, a 13.2% decline over 30 days, a 20.6% decline year to date and a 3.1% decline over the past year, set against a 32.1% gain over 3 years and a 42.2% decline over 5 years. Recent headlines around...
SEHK:2507
SEHK:2507Aerospace & Defense

Assessing Cirrus Aircraft (SEHK:2507) Valuation After Strong 2025 Results And Higher Final Dividend Proposal

Cirrus Aircraft (SEHK:2507) is drawing fresh attention after reporting full year 2025 results, with sales of US$1,354.37 million, net income of US$138.88 million, and a proposed final dividend of US$0.12 per share. See our latest analysis for Cirrus Aircraft. The latest earnings and dividend proposal have arrived during a weak patch for the shares, with a 1 month share price return showing a 39.93% decline and a 1 year total shareholder return showing a 6.9% decline, while a 1 day gain of...
NYSE:JBL
NYSE:JBLElectronic

How Jabil’s Higher 2026 Revenue Outlook and GLP‑1 Exposure At Jabil (JBL) Has Changed Its Investment Story

In March 2026, Jabil Inc. reported second-quarter results showing year-on-year growth in sales and net income, and issued third-quarter guidance calling for net revenue between US$8.10 billion and US$8.90 billion, U.S. GAAP operating income of US$398 million to US$458 million, and diluted EPS of US$2.36 to US$2.76. The company also lifted its full-year fiscal 2026 outlook to US$34.00 billion in revenue, underscoring how healthcare exposure and injector-pen manufacturing for weight-loss drugs...
SWX:NOVN
SWX:NOVNPharmaceuticals

A Look At Novartis (SWX:NOVN) Valuation After Recent Mixed Share Price Performance

Novartis (SWX:NOVN) is back in focus after recent share price moves, with the stock showing mixed returns over the past month and past 3 months. This puts current valuation and fundamentals under the spotlight for investors. See our latest analysis for Novartis. The recent share price pullback, with a 1 month share price return of a 5.5% decline after a stronger 3 month share price return of 12%, comes against a backdrop of stronger long term total shareholder returns of 30.7% over 1 year and...